Your browser doesn't support javascript.
loading
Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.
Ueno, Mikako; Iwata-Yoshikawa, Naoko; Matsunaga, Akihiro; Okamura, Tadashi; Saito, Sho; Ashida, Shinobu; Yoshida, Isao; Nagashima, Mami; Asakura, Hiroyuki; Yaoita, Yuu; Suzuki, Jun; Sadamasu, Kenji; Yoshimura, Kazuhisa; Kutsuna, Satoshi; Shiwa-Sudo, Nozomi; Nagata, Noriyo; Suzuki, Tadaki; Suzuki, Akinori; Okamoto, Miwa; Kimura, Moto; Ohmagari, Norio; Miura, Ryu; Ishizaka, Yukihito.
Afiliação
  • Ueno M; Department of Intractable Diseases, National Center for Global Health and Medicine, Tokyo, Japan.
  • Iwata-Yoshikawa N; Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
  • Matsunaga A; Department of Intractable Diseases, National Center for Global Health and Medicine, Tokyo, Japan.
  • Okamura T; Department of Laboratory Animal Medicine, National Center for Global Health and Medicine, Tokyo, Japan.
  • Saito S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Ashida S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Yoshida I; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Nagashima M; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Asakura H; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Yaoita Y; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Suzuki J; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Sadamasu K; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Yoshimura K; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Kutsuna S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Department of Infection Control, Graduate School of Medicine, Faculty of Medicine, Osaka University, Osaka, Japan.
  • Shiwa-Sudo N; Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
  • Nagata N; Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
  • Suzuki T; Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
  • Suzuki A; Sapporo Laboratory, EVEC, Inc., Hokkaido, Japan.
  • Okamoto M; Sapporo Laboratory, EVEC, Inc., Hokkaido, Japan.
  • Kimura M; Department of Academic-Industrial Partnerships Promotion, Center of Clinical Science, National Center for Global Health and Medicine, Tokyo, Japan.
  • Ohmagari N; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Miura R; Sapporo Laboratory, EVEC, Inc., Hokkaido, Japan. Electronic address: r-miura@evec.jp.
  • Ishizaka Y; Department of Intractable Diseases, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: zakay@ri.ncgm.go.jp.
Antiviral Res ; 201: 105297, 2022 05.
Article em En | MEDLINE | ID: mdl-35341809
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antineoplásicos Imunológicos / Tratamento Farmacológico da COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antineoplásicos Imunológicos / Tratamento Farmacológico da COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article